CN107157991A - 用于缓解尿频的延长释放制剂及其使用方法 - Google Patents

用于缓解尿频的延长释放制剂及其使用方法 Download PDF

Info

Publication number
CN107157991A
CN107157991A CN201710373440.5A CN201710373440A CN107157991A CN 107157991 A CN107157991 A CN 107157991A CN 201710373440 A CN201710373440 A CN 201710373440A CN 107157991 A CN107157991 A CN 107157991A
Authority
CN
China
Prior art keywords
release
analgestic
polymer
acid
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710373440.5A
Other languages
English (en)
Chinese (zh)
Inventor
大卫·A·迪尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellesley Pharmaceuticals LLC
Original Assignee
Wellesley Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/424,000 external-priority patent/US8236857B2/en
Priority claimed from US13/487,348 external-priority patent/US20120244221A1/en
Application filed by Wellesley Pharmaceuticals LLC filed Critical Wellesley Pharmaceuticals LLC
Publication of CN107157991A publication Critical patent/CN107157991A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201710373440.5A 2012-03-19 2013-03-13 用于缓解尿频的延长释放制剂及其使用方法 Pending CN107157991A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13/424,000 US8236857B2 (en) 2010-07-08 2012-03-19 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/424,000 2012-03-19
US13/487,348 US20120244221A1 (en) 2010-07-08 2012-06-04 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/487,348 2012-06-04
CN201380015062.3A CN104302284A (zh) 2012-03-19 2013-03-13 用于缓解尿频的延长释放制剂及其使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380015062.3A Division CN104302284A (zh) 2012-03-19 2013-03-13 用于缓解尿频的延长释放制剂及其使用方法

Publications (1)

Publication Number Publication Date
CN107157991A true CN107157991A (zh) 2017-09-15

Family

ID=49223209

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201710373440.5A Pending CN107157991A (zh) 2012-03-19 2013-03-13 用于缓解尿频的延长释放制剂及其使用方法
CN201380015062.3A Pending CN104302284A (zh) 2012-03-19 2013-03-13 用于缓解尿频的延长释放制剂及其使用方法
CN201380015025.2A Pending CN104321056A (zh) 2012-03-19 2013-03-14 用于缓解尿频的延长释放制剂及其使用方法
CN201711086139.2A Pending CN107789626A (zh) 2012-03-19 2013-03-14 用于缓解尿频的延长释放制剂及其使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201380015062.3A Pending CN104302284A (zh) 2012-03-19 2013-03-13 用于缓解尿频的延长释放制剂及其使用方法
CN201380015025.2A Pending CN104321056A (zh) 2012-03-19 2013-03-14 用于缓解尿频的延长释放制剂及其使用方法
CN201711086139.2A Pending CN107789626A (zh) 2012-03-19 2013-03-14 用于缓解尿频的延长释放制剂及其使用方法

Country Status (15)

Country Link
EP (2) EP2827852A4 (xx)
JP (5) JP2015510928A (xx)
KR (4) KR20140134333A (xx)
CN (4) CN107157991A (xx)
AU (4) AU2013235518B2 (xx)
BR (2) BR112014020271A8 (xx)
CA (2) CA2866853A1 (xx)
HK (3) HK1204553A1 (xx)
MX (3) MX2014011128A (xx)
MY (2) MY174090A (xx)
NZ (6) NZ712594A (xx)
RU (3) RU2669565C2 (xx)
SG (2) SG11201500408VA (xx)
WO (2) WO2013142197A1 (xx)
ZA (2) ZA201405862B (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
MX2016001030A (es) 2013-07-23 2016-10-07 Allergan Inc Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico.
KR20170010440A (ko) * 2014-06-06 2017-01-31 웰즐리 파마슈티컬스 엘엘씨 배뇨 빈도를 감소시키기 위한 약학적 제형 및 이의 사용방법
KR101809908B1 (ko) 2014-07-21 2018-01-25 주식회사 종근당 5-알파환원효소억제제를 포함하는 조성물
US10286033B2 (en) * 2014-11-20 2019-05-14 Serenity Pharmaceuticals, Llc Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist
AU2016331879A1 (en) * 2015-09-30 2018-05-17 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
CN108391420A (zh) * 2015-09-30 2018-08-10 韦尔斯利医药有限公司 用于减少排尿频率的组合物及其制备方法和应用
CN105238124B (zh) * 2015-11-16 2018-02-09 太仓东能环保设备有限公司 一种抗菌腻子粉
JP6294924B2 (ja) 2016-09-05 2018-03-14 株式会社Ｓｕｂａｒｕ 車両の走行制御装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040942A1 (fr) * 1998-02-10 1999-08-19 Yoshitomi Pharmaceutical Industries, Ltd. Preparations a liberation controlee
US20020102309A1 (en) * 1999-09-14 2002-08-01 Jane C. I. Hirsh Controlled release formulation for administration of an anti-inflammatory naphthalene derivative
DE10116978A1 (de) * 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
AU2003211078A1 (en) * 2002-02-19 2003-09-09 Pharmacia Corporation Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
RU2004135563A (ru) * 2002-06-07 2005-06-10 Яманоути Фармасьютикал Ко.,Лтд. (Jp) Лекарственное средство для лечения повышенной активности мочевого пузыря
US20040054008A1 (en) * 2002-09-13 2004-03-18 Tohru Araki Medicament for treatment of nocturia
KR100742001B1 (ko) * 2003-03-21 2007-07-23 다이노젠 파마세우티컬스, 인코포레이티드 평활근 모듈레이터 및 알파2 델타 서브유닛 칼슘 채널모듈레이터를 이용한 하부 요로 질환의 치료 방법
KR101113005B1 (ko) * 2003-03-21 2012-02-24 맥네일-피피씨, 인코포레이티드 비-스테로이드계 항염증성 약물 투여법
EP1627876A1 (en) * 2004-08-20 2006-02-22 Ferring B.V. Heterocyclic condensed compounds useful as antidiuretic agents
EP2248524A3 (en) * 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
US20070021357A1 (en) * 2005-06-17 2007-01-25 Dynamis Therapeutics, Inc. Treatment of inflammatory conditions
US20080085314A1 (en) * 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
JP5312027B2 (ja) * 2005-09-02 2013-10-09 セラヴィダ、インク 病気の治療法
WO2010138441A1 (en) * 2009-05-28 2010-12-02 Aptapharma, Inc. Multilayer oral tablets containing a non-steroidal anti-inflammatory drug and/or acetaminophen
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
US20120244221A1 (en) * 2010-07-08 2012-09-27 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OSAMU YOKOYAMA等: "Zolpidem Increases Bladder Capacity and Decreases Urine Excretion in Rats", 《NEUROUROLOGY AND URODYNAMICS》 *

Also Published As

Publication number Publication date
CN104302284A (zh) 2015-01-21
NZ628079A (en) 2016-05-27
RU2016133305A3 (xx) 2018-12-10
MX2019008817A (es) 2019-09-26
JP2015510936A (ja) 2015-04-13
NZ714288A (en) 2016-12-23
CN104321056A (zh) 2015-01-28
AU2017203139B2 (en) 2018-07-19
AU2013235518A2 (en) 2014-10-09
RU2016133305A (ru) 2018-12-10
NZ630471A (en) 2016-04-29
AU2013235518A1 (en) 2014-09-25
RU2014142025A (ru) 2016-05-10
NZ712594A (en) 2016-09-30
CN107789626A (zh) 2018-03-13
EP2827851A1 (en) 2015-01-28
HK1204553A1 (en) 2015-11-27
AU2017203139A1 (en) 2017-06-01
WO2013142197A1 (en) 2013-09-26
EP2827852A4 (en) 2016-03-02
ZA201406146B (en) 2016-08-31
BR112014020113A8 (pt) 2017-07-11
ZA201405862B (en) 2016-08-31
AU2017203246A1 (en) 2017-06-08
WO2013142274A1 (en) 2013-09-26
BR112014020271A8 (pt) 2017-07-11
CA2866853A1 (en) 2013-07-26
KR20140134333A (ko) 2014-11-21
BR112014020113A2 (xx) 2017-06-20
MX2014011128A (es) 2015-08-10
RU2599017C2 (ru) 2016-10-10
AU2013235507B2 (en) 2017-03-23
KR20140134284A (ko) 2014-11-21
EP2827851A4 (en) 2015-10-14
AU2013235518B2 (en) 2017-03-02
EP2827852A1 (en) 2015-01-28
KR20170015537A (ko) 2017-02-08
JP2015510928A (ja) 2015-04-13
CA2866755A1 (en) 2013-09-26
HK1243921A1 (zh) 2018-07-27
SG11201500408VA (en) 2015-03-30
MX2014011129A (es) 2015-08-10
JP2018138602A (ja) 2018-09-06
MY175764A (en) 2020-07-08
JP2016172752A (ja) 2016-09-29
JP2018024693A (ja) 2018-02-15
AU2013235507A1 (en) 2014-08-21
AU2017203246B2 (en) 2018-10-18
MY174090A (en) 2020-03-09
SG11201500409SA (en) 2015-03-30
HK1251469A1 (zh) 2019-02-01
RU2669565C2 (ru) 2018-10-12
NZ718163A (en) 2017-09-29
KR20190003840A (ko) 2019-01-09
RU2014142066A (ru) 2016-05-10
BR112014020271A2 (xx) 2017-06-20
NZ714662A (en) 2016-08-26

Similar Documents

Publication Publication Date Title
CN107157991A (zh) 用于缓解尿频的延长释放制剂及其使用方法
AU2017203418B2 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
US20120135050A1 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
US8236857B2 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
US20120244221A1 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
CN107335057A (zh) 用于缓解尿频的药物制剂及其使用方法
CN107569690A (zh) 用于缓解尿频的延长释放制剂及其使用方法
CN107648212A (zh) 用于缓解尿频的缓释制剂及其使用方法
US10792261B2 (en) Extended, delayed and immediate release formulation method of manufacturing and use thereof
CN108391420A (zh) 用于减少排尿频率的组合物及其制备方法和应用
CN108135870A (zh) 延缓、延迟和立即释放型制剂及其制造方法和用途
CN108430465A (zh) 用于缓解尿频的组合物、其制造方法和用途
CN108289891A (zh) 缓解尿频的组合物，其制造方法和应用
EP2612663A1 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
TWI587879B (zh) 用於減少排尿頻率的延長釋放製劑及其使用方法
EP2612660B1 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
WO2013103357A1 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
TWI590822B (zh) 用於減少排尿頻率的延遲釋放製劑及其使用方法
CN108348487A (zh) 延迟释放制剂、其制备方法和用途
CN108601782A (zh) 用于缓解尿频的组合物，其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1243921

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20170915

RJ01 Rejection of invention patent application after publication